| SPECIES: | Human, Mouse |
| SOURCE SPECIES: | CHO cells |
| SEQUENCE: | The receptor-binding domain of human FLT3L is fused at the N-terminus to the Fc portion of human IgG1. |
| FUSION TAG: | Fc Tag |
| TESTED APPLICATIONS: | |
| APPLICATIONS: | This recombinant proteins is for research use only. |
| BIOLOGICAL ACTIVITY: | In vitro and in vivo generation of conventional and plasmacytoid dendritic cells (DC). FLT3L increases in vivo both NK and DC cells numbers in the spleen when mice are injected intraperitoneally with 2 or 10 ug, daily for 10 days (slightly higher effect at 10 ug). |
Specifications| PURITY: | >95% (SDS-PAGE). Endotoxin level is less than 0.1EU/ μg purified protein (LAL test; Lonza). |
| PHYSICAL STATE: | Liquid |
| BUFFER: | In PBS (sterile). |
| CONCENTRATION: | 1mg/ml |
| STORAGE CONDITIONS: | Stable for at least 6 months after receipt when stored at -20˚C. |
| ALTERNATE NAMES: | FMS-like Tyrosine Kinase 3 Ligand |
| ACCESSION NO.: | P49771 |
| PROTEIN GI NO.: | 1706818 |
| OFFICIAL SYMBOL: | FLT3LG |
| GENE ID: | 2323 |
| BACKGROUND: | FMS-like tyrosine kinase 3 ligand (FLT3L) acts as a growth factor that increases the number of immune cells (lymphocytes (B cells and T cells)) by activating the hematopoietic progenitors. It binds to FLT3 (CD135) which is found on multipotent progenitor (MPP) and common lymphoid progenitor (CLP) cells in mice. FLT3L induces the mobilization of the hematopoietic progenitors and stem cells in vivo which may help the system to kill cancer cells. FLT3L is crucial for steady-state pDC (plasmacytoid dendritic cells) and cDC (classical dendritic cells) development. Deficiency of FLT3L causes a dramatic decrease in DC numbers, whereas increasing its availability increase in DC numbers. |
FOR RESEARCH USE ONLY.
For additional information, visit ProSci's Terms & Conditions Page.
